Bimagrumab与Semaglutide联合使用在肥胖治疗研究中显示可减少脂肪同时保留肌肉质量-动脉网

Combination of Bimagrumab and Semaglutide Shown to Reduce Fat While Preserving Muscle Mass in Obesity Treatment Study

GeneOnline 等信源发布 2025-07-08 17:07



可切换为仅中文







by Mark Chiang

马克·蒋

Share To

分享到

A recent study presented at the American Diabetes Association (ADA) 2025 conference highlights findings on a combination therapy involving bimagrumab and semaglutide. Researchers report that this dual approach significantly enhances fat loss while simultaneously preserving muscle mass, marking a potential advancement in obesity treatment strategies..

美国糖尿病协会 (ADA) 2025 会议上发表的一项最新研究强调了比马鲁单抗与司美格鲁肽联合疗法的发现。研究人员报告称，这种双重方法在显著减少脂肪的同时保留了肌肉质量，标志着肥胖症治疗策略的潜在进步。

The investigation focused on the effects of combining bimagrumab, an antibody known for its ability to promote muscle growth, with semaglutide, a medication commonly used to manage type 2 diabetes and support weight loss. Results indicate that participants experienced notable reductions in body fat without compromising lean muscle tissue.

研究聚焦于将促进肌肉生长的抗体比马鲁单抗与常用于治疗2型糖尿病和支持减重的司美格鲁肽结合使用的效果。结果显示，参与者在减少体脂的同时并未影响瘦肌肉组织。

This outcome addresses a common challenge in obesity treatments where weight loss often includes both fat and muscle reduction. The findings suggest that this combination therapy may offer a more targeted approach to improving body composition in individuals managing obesity. Further research is expected to explore its long-term efficacy and safety profile..

该结果针对肥胖症治疗中常见的一个挑战，即体重减轻通常包括脂肪和肌肉的双重减少。研究结果表明，这种组合疗法可能为管理肥胖症的个体提供一种更具针对性的改善身体组成的方法。预计进一步的研究将探索其长期有效性和安全性。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源：GO-AI-ne1

Date: June 24, 2025

日期：2025年6月24日

相关内容：

Pharmaceutical Firms Partner with CDMOs to Streamline Operations and Reduce Capital Expenditures.

制药公司与CDMO合作以简化运营并减少资本支出。

Vaccine Effectiveness Maximized by Adhering to Recommended Dose Schedules.

遵循推荐的剂量计划可使疫苗效果最大化。